Drug news
EU approves Promus Premier Stent (Boston Scientific) for treating CAD
Boston Scientific has received CE Mark approval for the Promus Premier everolimus-eluting platinum chromium Coronary Stent System, the company's next-generation polymer drug-eluting stent (DES) technology for treating Coronary Artery Disease, and is starting its European market launch. The Promus Premier features a customized Platinum Chromium (PtCr) stent architecture, the everolimus drug coating and fluorinated co-polymer, and an enhanced stent delivery system. The everolimus drug and fluorinated co-polymer stent coating have been studied in multiple randomized clinical trials demonstrating long-term safety and efficacy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins